IP Library › Granted Patent US 12,377,176
Granted Patent B2
US 12,377,176 · App. 17/427,006 · Granted Aug 5, 2025

Cancer diagnostic imaging agents

Inventors: Alexander Josef Wurzer (Munich, DE); Hans-Jürgen Wester (Ilmmünster, DE); Matthias Johannes Eiber (Vaterstetten, DE)
Assignees: Technische Universität München; Technische Universität München—Klinikum Rechts der Isar
A61K51/0497A61K51/0482A61K51/1027C07B59/004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,176
App. No.
17/427,006
Granted
Aug 5, 2025
Kind
B2
Abstract

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.

Claims (7)

1. A compound having a chemical structure:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical or diagnostic composition comprising or consisting of one or more conjugates in accordance with claim 1 .

3. A method of imaging and/or diagnosing cancer comprising administering a conjugate according to claim 1 to a patient in need thereof.

4. A method of treating cancer comprising administering a conjugate according to claim 1 to a patient in need thereof.

5. A method of reducing neoangiogenesis/angiogenesis comprising administering a conjugate according to claim 1 to a patient in need thereof.

6. A method according to claim 4 wherein the cancer is prostate, breast, lung, colorectal or renal cell carcinoma.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2022
From: EIBER, MATTHIAS JOHANNES
To: TECHNISCHE UNIVERSITÄT MÜNCHEN - KLINIKUM RECHTS DER ISAR
Reel/Frame 059630/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2022
From: WURZER, ALEXANDER JOSEF; WESTER, HANS-JÜRGEN
To: TECHNISCHE UNIVERSITÄT MÜNCHEN
Reel/Frame 059630/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: WURZER, ALEXANDER JOSEF; WESTER, HANS-JÜRGEN
To: TECHNISCHE UNIVERSITÄT MÜNCHEN
Reel/Frame 058826/0082 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: EIBER, MATTHIAS JOHANNES
To: TECHNISCHE UNIVERSITÄT MÜNCHEN - KLINIKUM RECHTS DER ISAR
Reel/Frame 058827/0137 →
Priority Claims (1)
EP 19154495 · Jan 30, 2019 · regional
Continuity (1)
Related Publication 20220118120A1 · Apr 21, 2022
References Cited (21)
US 11497819B2 · Wester · 2022 [cited by examiner]
US 20200197545A1 · Wurzer et al. · 2020 [cited by applicant]
CN 102626522 · 2012 [cited by applicant]
WO 2016062370A1 · 2016 [cited by applicant]
WO 2019020831A1 · 2019 [cited by applicant]
WO WO2019115547A1 · 2019 [cited by examiner]
Banjeree (Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate Specific Membrane Antigen for Dosimetry Estimates, 2015, The Journal of Nuclear Medicine, 56:4) (Year: 2015). [cited by examiner]
Litau (Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics, 2015, Bioconjugate Chemistry, 26:235… [cited by examiner]
Linder (Synthesis and in Vitro and in Vivo Evaluation of SiFA-Tagged Bombesin and RGD Peptides as Tumor Imaging Probes for Positron Emission Tomography, Mar. 25, 2014, Bioconjugate Chemistry, 25:738-749) (Year: 2014). [cited by examiner]
U.S. Appl. No. 16/634,759, filed Jan. 28, 2020, 2020-0197545, Published. [cited by applicant]
U.S. Appl. No. 17/426,962, filed Jul. 29, 2021, Pending. [cited by applicant]
Bailey et al., Silicon/Fluorine-18/PSMA: A winning team for PET imaging of prostate cancer. 22nd International Symposium on Radiopharmaceutical Sciences. J Label Compd Radiopharm. 2017;60(Suppl 1):S353, Poster p. 190. [cited by applicant]
Banerjee et al., Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed Engl. Sep. 19, 2011;50(39):9167… [cited by applicant]
Bernard-Gauthier et al., From Unorthodox to Established: The Current Status of (18)F-Trifluoroborate- and (18) F-SiFA-Based Radiopharmaceuticals in PET Nuclear Imaging. Bioconjug Chem. Feb. 17, 2016;27(2):267-79. [cited by applicant]
Carroll et al., Orthogonal 18F and 64Cu labelling of functionalised bis(thiosemicarbazonato) complexes. Chem Commun (Camb). Jun. 21, 2010;46(23):4052-4. [cited by applicant]
Hueting et al., A dual radiolabelling approach for tracking metal complexes: investigating the speciation of copper bis (thiosemicarbazonates) in vitro and in vivo. Metallomics. May 2015;7(5):795-804. [cited by applicant]
Lindner et al., Synthesis and in vitro and in vivo evaluation of SiFA-tagged bombesin and RGD peptides as tumor imaging probes for positron emission tomography. Bioconjug Chem. Apr. 16, 2014;25(4):738-49. [cited by applicant]
Litau et al., Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics. Bioconjug Chem. Dec. 16, 2015… [cited by applicant]
Lutje et al., PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics. Oct. 18, 2015;5(12):1388-401. [cited by applicant]
Westelrund et al., Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. Mol Pharm. May 2, 2016;13(5)… [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/052268, dated Apr. 6, 2020, 9 pages. [cited by applicant]